176982-57-3

Basic information

• Product Name: (S)-3-BOC-AMINO-BUTYLAMINE
• Synonyms: (S)-3-BOC-AMINO-BUTYLAMINE;Carbamic acid, [(1S)-3-amino-1-methylpropyl]-, 1,1-dimethylethyl ester (9CI);(S)-3-Boc-aminobutylamine hydrochloride;Carbamic acid, N-[(1S)-3-amino-1-methylpropyl]-, 1,1-dimethylethyl ester;3-N-Boc-butane-1,3-diamine-HCl;tert-butyl (2S)-4-aMino-2-(aMinoMethyl)butanoate;3-N-Boc-Butane-1,3-diaMine hydrochloride;3(S)-Boc-aMino-butylaMine
• CAS NO: 176982-57-3
• Molecular Formula: C₉H₂₀N₂O₂
• Molecular Weight: 188.27
• Product Categories: N-BOC
• Mol File: 176982-57-3.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 282.6 °C at 760 mmHg
• Flash Point: 124.7 °C
• Appearance: /
• Density: 0.972g/cm³
• Vapor Pressure: 0.00333mmHg at 25°C
• Refractive Index: 1.455
• Storage Temp.: 2-8°C(protect from light)
• Solubility: DMSO (Slightly), Methanol (Slightly)
• CAS DataBase Reference: (S)-3-BOC-AMINO-BUTYLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-3-BOC-AMINO-BUTYLAMINE(176982-57-3)
• EPA Substance Registry System: (S)-3-BOC-AMINO-BUTYLAMINE(176982-57-3)

Safety Data

• Hazardous Substances Data: 176982-57-3(Hazardous Substances Data)

Usage

Uses

(S)-3-Boc-Amino-butylamine Hydrochloride, is used to prepare macrocyclic Hsp90 inhibitors as metabolically stabile potential antitumor agents.

InChI:InChI=1/C9H20N2O2/c1-7(5-6-10)11-8(12)13-9(2,3)4/h7H,5-6,10H2,1-4H3,(H,11,12)/t7-/m0/s1

Upstream product

• 126301-16-4 (2S)-2-[(tert-butoxycarbonyl)amino]propyl methanesulfonate 
• 79069-13-9 (S)-2-t-butoxycarbonylaminopropan-1-ol 
• 24424-99-5 di-tert-butyl dicarbonate 
• 172695-22-6 (2-cyano-1(S)-methylethyl)carbamic acid, 1,1-dimethylethyl ester 

Downstream Products

• 176982-58-4 [1(S)-methyl-3-[(phenylmethyl)amino]propyl]carbamic acid, 1,1-dimethylethyl ester 
• 176982-59-5 3-[(3-cyanopropyl)(phenylmethyl)amino-1(S)-methylpropyl]carbamic acid, 1,1-dimethylethyl ester 
• 170367-73-4 3-[(4-aminobutyl)(phenylmethyl)amino-1(S)-methylpropyl]carbamic acid, 1,1-dimethylethyl ester 
• 252353-70-1 [3-[[4-(2,4-dioxo-3-oxazolidinyl)butyl](phynylmethyl)amino]-1-methylpropyl]carbamic acid, 1,1-dimethylethyl ester (S) 
• 170367-77-8 2,2,6-trimethyl-4,15-dioxo-9-(phenylmethyl)-3,16-dioxa-5,9,14-triazaoxadecan-18-oic acid (S) 
• 252353-89-2 [21-[[(1,1-dimethylethoxy)carbonyl]amino]-1,25,25-trimethyl-10,12,23-trioxo-4-(phenylmethyl)-24-oxa-4,9,13,20,22-pentaaza-21-hexacosen-1-yl]carbamic acid, 1,1-dimethylethyl ester (S) 
• 170367-79-0 [4-[[3-[[(1,1-dimethylethoxy)carbonyl]amino]butyl](phenylmethyl)amino]butyl]carbamic acid, 11-[[(1,1-dimethylethoxy)carbonyl]amino]-15,15-dimethyl-2,13-dioxo-14-oxa-3,4,12-triaza-11-hexadecen-1-yl ester (S) 
• 1327336-78-6 C₂₉H₃₇BrN₄O₄ 
• 1301178-02-8 C₂₉H₃₉BrN₄O₃ 
• 932032-36-5 (S)-N¹²-(tert-butyloxycarbonyl)-N⁹-(o-nitrophenylsulfonyl)-1,12-diamino-4,9-diazatridecane 
• 932032-35-4 (S)-N⁵-(o-nitrophenylsulfonyl)-N⁸-(tert-butyloxycarbonyl)-8-amino-5-aza-1-iodononane 
• 875681-02-0 (S)-N¹-phthaloyl-N⁵-(o-nitrophenylsulfonyl)-N⁸-(tert-butyloxycarbonyl)-1,8-diamino-5-azanonane 
• 949916-62-5 (3S)-N¹-(benzyloxycarbonyl)-N³-(tert-butyloxycarbonyl)-1,3-diaminobutane 
• 875680-99-2 (S)-N¹-(o-nitrophenylsulfonyl)-N³-(tert-butyloxycarbonyl)-1,3-diaminobutane 

Relevant articles and documents

Entropy-controlled catalytic asymmetric 1,4-type Friedel-crafts reaction of phenols using conformationally flexible guanidine/bisthiourea organocatalyst

Soft and weak cooperation: Conformationally flexible organic compounds were found to promote the title transformation. These "soft" organocatalysts, which are able to control processes through the differential activation entropies (ΔΔS*S-R) of

α-methyl polyamines: Efficient synthesis and tolerance studies in vivo and in vitro. First evidence for dormant stereospecificity of polyamine oxidase

Efficient syntheses of metabolically stable α-methylspermidine 1, α-methylspermine 2, and bis-α,α-methylated spermine 3 starting from ethyl 3-aminobutyrate are described. The biological tolerance for these compounds was tested in wild-type mice and transgenic mice carrying the metallothionein promoter-driven spermidine/spermine N1- acetyltransferase gene (MT-SSAT). The efficient substitution of natural polyamines by their derivatives was confirmed in vivo with the rats harboring the same MT-SSAT transgene and in vitro with the immortalized fibroblasts derived from these animals. Enantiomers of previously unknown 1-amino-8-acetamido-5-azanonane dihydrochloride 4 were synthesized starting from enantiomerically pure (R)- and (S)-alaninols. The studies with recombinant human polyamine oxidase (PAO) showed that PAO (usually splits achiral substrates) strongly favors the (R)-isomer of 4 that demonstrates for the first time that the enzyme has hidden potency for stereospecificity.

Structure - Immunosuppressive activity relationships of new analogues of 15-deoxyspergualin. 2. Structural modifications of the spermidine moiety

A series of new analogues of 15-deoxyspergualin (DSG), an immunosuppressive agent commercialized in Japan, was synthesized and tested in a graft-versus-host disease (GVHD) model in mice. Various substitutions of the spermidine 'D' region were made in order to determine its optimum structure in terms of in vivo immunosuppressive activity. Various positions of methylation were first investigated leading to the discovery of the monomethylated malonic derivative 56h in which the pro-R hydrogen of the methylene α to the primary amine of the spermidine moiety has been replaced by a methyl group. Synthesis of the similarly methylated analogue of the previously reported glycolic derivative LF 08-0299 afforded 60c which demonstrated a powerful activity at a dose as low as 0.3 mg/kg in the GVHD model and was much more potent than DSG in the demanding heart allotransplantation model in rats. The improvement of in vivo activity was supposed to be related to an increase of the metabolic stability of the methylated analogues compared to the parent molecules. Due to its very low active dose, compatible with a subcutaneous administration in humans, and its favorable pharmacological and toxicological profile, 60e was selected as a candidate for clinical evaluation.